Chondrosarcoma is a heterogeneous collection of malignant bone tumors and is the second most common primary malignancy of bone after osteosarcoma. Recent work has identified frequent, recurrent mutations in IDH1 or IDH2 in nearly half of central chondrosarcomas. However, there has been little systematic genomic analysis of this tumor type, and, thus, the contribution of other genes is unclear. Here we report comprehensive genomic analyses of 49 individuals with chondrosarcoma (cases). We identified hypermutability of the major cartilage collagen gene COL2A1, with insertions, deletions and rearrangements identified in 37% of cases. The patterns of mutation were consistent with selection for variants likely to impair normal collagen biosynthesis. In addition, we identified mutations in IDH1 or IDH2 (59%), TP53 (20%), the RB1 pathway (33%) and Hedgehog signaling (18%).
We subjected 49 cases of untreated chondrosarcoma, including 30 central, 4 peripheral and 14 dedifferentiated tumors and 1 tumor arising in an individual with synovial chondromatosis, along with matching normal tissues to whole-exome sequencing as previously described 1 . Dedifferentiated chondrosarcoma is characterized by biphasic histology represented by conventional chondrosarcoma abutting a high-grade non-cartilaginous component. For dedifferentiated chondrosarcoma, we obtained sequence from the high-grade noncartilaginous component of the tumor in each case. Case distribution by grade is shown in Supplementary Table 1. Exomic sequence coverage at a minimum depth of 30× was 65-70%, and data were processed as previously described 1 . We confirmed sequence variants as somatic using custom targeted capture and sequencing combined with manual data inspection. Candidate genes were assessed in an extension series of 26 cases (Supplementary Table 1) . Allele-specific copy number was assessed with SNP6.0 arrays and direct analyses of exome reads as previously described 1, 2 .
In total, we identified 1,428 somatic mutations, with somatic mutation burden ranging from 1 to 115 per case (Supplementary Table 2 ). Mutations comprised 944 missense, 61 nonsense, 37 essential splicesite and 301 synonymous changes, 80 indels and 5 substitutions in microRNAs. Somatic mutation burden showed significant association with higher tumor grade. High-grade tumors (grades 2 and 3 and dedifferentiated) had on average more than double the number of somatic mutations per sample as grade 1 chondrosarcoma (Wilcoxon rank-sum test P = 0.00017).
The most notable finding of this study was the identification of mutations in COL2A1, which encodes the α chain of type II collagen fibers, the major collagen constituent of articular cartilage. We initially identified somatic mutations in eight cases from the exome screen that were all small indels. This striking pattern of mutations prompted a more thorough investigation of COL2A1 to look for rearrangements in addition to point mutations. We tiled the entire gene footprint with baits for custom capture and subjected all exome cases as well as the 26 follow-up tumors to capture and sequencing. In total, 44% (33/75) of cases had at least 1 mutation that was predicted to affect coding sequence (Fig. 1, Supplementary Fig. 1 and Supplementary Table 3) . The mutations consisted of splice-site changes (n = 2), indels (n = 23), missense changes (n = 2) and large-scale rearrangements (n = 36). We identified no synonymous mutations (Supplementary Table 3 ). The majority of rearrangements had both breakpoints located within the footprint of COL2A1 (Supplementary Fig. 2) , and none was predicted to result in an in-frame fusion event. Whole-genome shotgun sequencing at low depth in six of the chondrosarcoma cases showed that breakpoints were clustered in COL2A1 and that chromosome 12 was not highly rearranged elsewhere (Supplementary Fig. 2) . In 13 cases, we identified a single COL2A1 mutation; however, Frequent mutation of the major cartilage collagen gene COL2A1 in chondrosarcoma l e t t e r s 20 tumors had more than 1 mutation in this gene. A one-sided Fisher's exact test indicated that, of all cases, high-grade tumors (grades 2 and 3 and dedifferentiated) were significantly more likely to contain a COL2A1 mutation than low-grade tumors (grade 1) (P = 0.029). This association between COL2A1 mutation and tumor grade, however, was not significant when only central chondrosarcoma cases were considered (P = 0.093).
Although finding 20 cases with more than 1 COL2A1 mutation is formally compatible with a loss-of-function mechanism, the presence of multiple cases with a single heterozygous mutation suggests that functional consequences at the protein level may be more complex. We therefore performed immunohistochemistry for COL2A1 protein on 43 available tumors (22 mutation positive and 21 wild type; Supplementary Table 4) . We observed abnormal staining (absent or focal compared to the diffuse staining seen in normal cartilage; Supplementary Fig. 3 ) in 31 of 43 tumors, with absence of staining in 8 tumors and focal staining in 23. Of the eight cases with no staining, six encoded mutant COL2A1, with only one having two mutations identified in the gene. Of the 23 cases showing focal staining, 12 encoded mutant COL2A1 (2 cases with more than 1 mutation), and 11 had no detectable mutation. It is possible that COL2A1 mutations in a proportion of the seemingly wild-type cases have not been detected, in particular, given the complex nature of the rearrangements that predominate, or have otherwise aberrant type II collagen deposition for reasons that remain obscure. These data argue that complete loss of protein is not the predominant outcome of COL2A1 mutation.
We also sequenced the entire COL2A1 gene in 56 osteosarcomas, 24 chordomas, 10 other cartilaginous tumors and 73 meningiomas to compare patterns of mutation. The results showed an accumulation of mutations across the gene footprint of COL2A1 that was restricted to chondrosarcomas (Supplementary Table 5 ). This pattern suggested that COL2A1 is hypermutable in chondrosarcoma. Given that COL2A1 is transcribed at a substantial rate in chondrocytes, the data may support the notion of a transcription-associated mutation or recombination (TAM or TAR) mechanism 3 . Elevated COL2A1 mutation rate does not preclude mutations from having biological consequences. Analyses of the patterns of mutation provided evidence of selection. No silent coding mutations were found. There was a preponderance of frameshifting indels compared to substitution mutations in exons (Supplementary Table 6a ). In COL2A1 introns, these mutation classes were in equal proportion. Considering only indels, there were very few mutations in coding sequence that were multiples of three (in frame) compared to the noncoding portions of the gene (Supplementary Table 6b ). These data suggest positive selection for mutations predicted to substantially disrupt COL2A1 coding potential. To further explore the specificity of COL2A1 mutation for chondrosarcoma, mutations across all collagen genes were assessed in multiple bone and cartilage tumors, including chondroblastomas (n = 6), chondromyxoid fibromas (n = 2), chordomas (n = 24) and osteosarcomas (n = 56). The results clearly indicate an enrichment for nonsynonymous mutations that was restricted to COL2A1 in chondrosarcomas ( Supplementary Fig. 4 ).
Mature collagen fibrils are formed via the assembly of pro-collagen α chains into triple-helix formations that are stabilized through post-translational modifications. Constitutive mutations of COL2A1 lead to a variety of skeletal and ocular disorders that range from lethal perinatal dwarfism, due to de novo missense mutations in achondrogenesis type II (MIM 200610), to Stickler syndrome type I (MIM 108300), caused primarily by familial truncating mutations. The variety of COL2A1 somatic mutations reported here in chondrosarcoma would likely lead to disruption of the collagen maturation process through the production of aberrant pro-collagen α chains, which might have dominant-negative effects, given the heterozygous nature of many of the mutations. In a mouse model carrying a dominant-negative Col2a1 mutation identified in the human disease spondyloepiphyseal dysplasia congenita (MIM 183900), depletion of collagen fibrils was found to significantly impair chondrocyte differentiation 4 . However, there is no reported increase in predisposition to chondrosarcoma in these human developmental disorders nor in their mouse models, similar to the lack of cancer predisposition found for the germline alleles of fibroblast growth factor receptor genes that give rise to other skeletal disorders. Of note, targeted Pten deficiency in mouse chondrocytes leads to dyschondroplasia resembling human enchondroma 5 . A dedifferentiated chondrosarcoma (PD6363a) found to have homozygous deletion of PTEN did not have COL2A1, IDH1 or IDH2 mutation. Lastly, of various extracellular matrix components, type 2 collagen was found to restore cartilaginous features of otherwise dedifferentiated primary chondrocytes in monolayer culture 6 . Thus, there is a rational basis to hypothesize that COL2A1 mutations in chondrosarcoma might not be merely passenger events but might bring about fundamental perturbation of matrix deposition and signaling that may contribute to oncogenesis through the abrogation of normal differentiation programs. These data indicate that the development of in vivo approaches for mechanistic investigation of COL2A1 in chondrosarcoma will be important.
As we previously reported, IDH1 and IDH2 mutations are prevalent in central chondrosarcoma 7 and absent from peripheral chondrosarcoma. We detected an IDH1 or IDH2 mutation in 29 of 49 tumors (59%) (Fig. 2) . A Fisher's exact test of difference in the proportion of tumors of different grades bearing an IDH1 or IDH2 mutation did not give a significant result (P = 0.22). Given the active development of inhibitors for mutant IDH proteins 8 , chondrosarcoma would be a compelling opportunity, as there are currently no effective treatments other than radical surgical resection. In addition, evaluation of 2-hydroxyglutarate, the oncometabolite produced by mutant IDH proteins, as a biomarker 9 in chondrosarcoma management is warranted.
We also identified frequent involvement of the RB1 pathway in chondrosarcoma (Figs. 2 and 3a) . Copy number analyses identified 13 tumors with homozygous deletions of CDKN2A, consistent with previous reports 10 ( Supplementary Fig. 5 and Supplementary Table 7) . We also identified a CDKN2A missense mutation encoding p.Asp108Gly, with loss of the wild-type allele, as well as two further truncating mutations in the extension tumor series. We found focal npg l e t t e r s amplifications of CDK4 (one case) and CDK6 (two cases), with one of the cases with CDK6 amplification also having a CDKN2A mutation. CDK4 was amplified together with MDM2, as has previously been reported 11 . CDK6, to the best of our knowledge, has not previously been found to be amplified in chondrosarcoma. Altogether, 33% (16/49) of exome-series cases had mutations affecting RB regulatory constituents. TP53 mutation have a key role in chondrosarcoma, with 20% (10/49) of cases having coding mutations.
Mutations of other known cancer-related genes included ones in SETD2, KDM6A, NF2, TET2, DNMT3A and TSC1. Germline EXT1 or EXT2 mutation was identified in three grade 1 peripheral chondrosarcoma. PD7299a, the case with the largest substitution burden, had a somatic MUTYH missense mutation previously reported in the context of colorectal cancer susceptibility in familial adenomatous polyposis 2 (MIM 608456) [12] [13] [14] [15] . We found evidence for the involvement of the Indian Hedgehog (IHH) signaling pathway in chondrosarcoma (Figs. 2 and 3b) . IHH signaling is crucial for normal chondrocyte differentiation. Mutations resulting in constitutive Hedgehog signaling are causal in benign cartilage tumors [16] [17] [18] . We identified four mutations of PTCH1 in the exome screen (two missense and two truncating) and a PTCH1 missense mutation in the extension tumor series (Fig. 2 and Supplementary  Table 2) . A single inactivating SUFU mutation and a single GLI1 amplification were also identified in separate cases. Further, we identified focal amplifications of RUNX2 and HHIP, which are both closely linked to IHH signaling 16, 17 . Taken together, there is mutational evidence for IHH pathway activation in 18% (9/49) of exome-series cases. Hedgehog pathway inhibition via the small molecule vismodegib targeting SMO has recently been shown to have significant activity in advanced basal cell carcinoma, including patients with basal-cell nevus syndrome due to Hedgehog pathway mutation 18 . Assessment of Hedgehog pathway inhibitors in the subset of patients with chondrosarcoma in whom mutations in this pathway have been identified may be an important line of therapeutic investigation.
Combined with our previous efforts identifying IDH1 and IDH2 mutations in central chondrosarcoma, the comprehensive analysis presented here begins to paint a more complete picture of chondrosarcoma genomics for the most common and most lethal subtypes. Aberrant RB and IHH pathways and fundamental perturbation of matrix biology via COL2A1 mutation, as discovered here, have been shown to likely contribute to chondrosarcoma. In addition to exploiting IDH1 and IDH2 mutations in therapeutic and biomarker contexts, delineating the contributions of RB and IHH pathway mutations presents opportunities for focused therapeutic exploration. Further, if the production of mature collagen fibrils is indeed compromised by mutant COL2A1, then there may be an opportunity to explore therapeutic strategies exploiting cellular and endoplasmic reticulum stress responses to improperly folded proteins. This study demonstrates oNLINe MeTHods Subject samples. Informed consent was obtained from all subjects, and ethical approval was obtained from the Cambridgeshire 2 Research Ethics Service (reference 09/H0308/165). Collection and use of subject samples were approved by the appropriate institutional review board (IRB) of each institution. In addition, this study and use of its collective materials had specific IRB approval.
Exome enrichment and sequencing. Genomic libraries were prepared using the Illumina Paired-End Sample Prep kit following the manufacturer's instructions. Enrichment was performed as described previously 19 using the Agilent SureSelect Human All Exon 50 Mb kit following the manufacturer's recommended protocol, with the exception that enrichment was not performed before PCR amplification. Each exome was sequenced using the 75-bp paired-end protocol on an Illumina HiSeq DNA Analyzer to produce approximately 10 Gb of sequence per exome. Sequencing reads were aligned to the human genome (NCBI Build 37) using the Burrows-Wheeler Aligner (BWA) algorithm with default settings 20 . Reads that were unmapped, PCRderived duplicates and reads mapping outside the targeted region of the genome were excluded from the analysis. Average exome sequence coverage at 30× or higher was 70%.
Enrichment and sequencing of target regions.
A custom-made bait set (Agilent) was designed to capture and enrich genomic regions of putative somatic variants and selected genes for follow-up, including CDKN1A, CDKN2A, COL11A1, COL11A2, COL2A1, COL9A1, COL9A2, COL9A3, DNMT3A, EXT1, EXT2, IDH1, IDH2, NF2, PTCH1, RB1, SETD2, SUFU, TET2 and TP53. The bait set was applied to the 49 primary tumor samples, to a chondrosarcoma follow-up series of 26 cases and to non-chondrosarcoma tumors. Enrichment and sequencing were performed as for the exomes.
Rearrangement screen. Six tumors (PD7054a, PD7061a, PD9388a, PD9390a, PD9391a and PD9394a) underwent low-sequence-depth whole-genome shotgun sequencing to identify rearrangements, as previously described 21 , with the exception that a read length of 50 bp was used instead of 37 bp.
Variant detection. The CaVEMan (cancer variants through expectation maximization) algorithm was used to call single-nucleotide substitutions 1 . This algorithm uses a naive Bayesian classifier to estimate the posterior probability of each possible genotype (wild type compared to germline or somatic mutation) at each base. We applied several post-processing filters to the set of initial CaVEMan mutation calls to remove variants reported in poor quality sequence and to improve the specificity of the output.
To call insertions and deletions, we used split-read mapping implemented as a modification of the Pindel algorithm 22 . Pindel searches for reads with one end anchored on the genome and the other end mapped with high confidence in two (split) portions, spanning a putative indel. Post-processing filters were applied to the output to improve specificity. To call rearrangements, we applied the Brass (breakpoint via assembly) algorithm, which identifies rearrangements by grouping discordant read pairs that represent the same breakpoint event 23 . Mutations were annotated to Ensembl version 58.
Variant validation.
All putative somatic variants identified in the primary screen of 49 tumors were subjected to targeted capture and were sequenced. Variants for which additional reads could not be generated were validated by manual inspection of sequencing data from the initial exome screen. COL2A1 rearrangements were validated, algorithmically or manually, by defining the exact location of the breakpoint at nucleotide-level resolution and by extracting split reads across the breakpoint. Additionally, 14 arbitrarily chosen breakpoints (39%) were validated by PCR (primer sequences available upon request). Rearrangements other than those affecting COL2A1 were not further validated.
Detection of copy number variation. SNP array hybridization on the SNP6.0 platform was carried out according to Affymetrix protocols and as described at the Sanger Institute website (see URLs) for 36 of 49 tumors from the exome screen. For the remaining 13 cases, copy number data were derived directly from exome sequencing data.
Copy number analysis was performed using ASCAT (version 2.2) 2 , taking into account non-neoplastic cell infiltration and tumor aneuploidy, and resulted in integral allele-specific copy number profiles for the tumor cells 5 . Homozygous deletions were called if there were zero copies in the tumor cells. Amplifications were defined as previously described 6 . Measures of nonneoplastic cell infiltration and tumor aneuploidy were derived by ASCAT 5 .
Immunohistochemistry. Immunohistochemistry was performed using standard techniques, including the chromogen diaminobenzidine, while employing the Bond-Max Autostainer (Novocastra), as previously described 24 . A monoclonal mouse primary antibody to human COL2A1 was used (Santa Cruz Biotechnology, sc-59958; 1:50 dilution). Semiquantitative assessment of staining was performed independently by two histopathologists.
Statistical analyses.
The significance of the association between tumor grade and overall somatic mutation burden was tested using the Wilcoxon rank-sum test. The significance of the association between COL2A1 mutation status and tumor grade was tested using one-sided Fisher's exact tests. The significance of the difference in the proportion of tumors of different grades bearing an IDH1 or IDH2 mutation was determined by Fisher's exact test and confirmed by χ 2 test for trend. The statistical significance of recurrence in mutated genes was assessed using a permutation method. First, the regions that were pulled down by baits were identified as those with coverage in at least three of four noncancerous samples, subject to the same pulldown procedure used in this study. Random mutations were generated in silico in these regions for each sample, with the number of simulated mutations equal to three times the number of substitutions observed in that sample. Simulated mutations were annotated using the Variant Effect Predictor 25 . Nonsynonymous mutations (those with an annotation of 'NON_SYNONYMOUS_CODING' , 'ESSENTIAL_SPLICE_ SITE' , 'STOP_GAINED' or 'STOP_LOST') were randomly selected in the same numbers as observed in our samples. This procedure was repeated 100,000 times, and, for each mutated gene, the number of runs that contained at least as many mutated samples as were observed in our data set, n, was noted. The probability that each gene would be mutated in the observed number of samples by chance was then determined by P = n/100,000. P values were adjusted using the Bonferroni correction, after which the only recurrently mutated gene with significantly more mutated samples than expected by chance was IDH1.
